Technical Analysis for BWAY - Brainsway Ltd.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| See historical BWAY trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Fell Below 50 DMA | Bearish | 0.00% | |
| Expansion Pivot Sell Setup | Bearish Swing Setup | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Crossed Above 50 DMA | Bullish | -2.95% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -2.95% | |
| Narrow Range Bar | Range Contraction | -2.95% | |
| NR7 | Range Contraction | -2.95% | |
| Inside Day | Range Contraction | -2.95% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/29/2019
- Sector: Healthcare
- Industry: Diagnostics & Research
Brainsway is a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), for which Brainsway received marketing authorization from the U.S. Food and Drug Administration (FDA) in 2013 (for MDD) and in August 2018 (for OCD). Brainsway is currently conducting clinical trials of Deep TMS in other psychiatric, neurological and addiction disorders, including smoking cessation and post-traumatic stress disorder, and is planning trials for opioid addiction, fatigue in multiple sclerosis (MS) and post-stroke rehabilitation.
Neuroscience Multiple Sclerosis Psychiatry Major Depressive Disorder Neuromodulation Neurophysiology Neurotechnology Obsessive Compulsive Disorder Treatment Of Major Depressive Disorder Neuropsychology Post Traumatic Stress Disorder Treatment Of Depression Fatigue
Neuroscience Multiple Sclerosis Psychiatry Major Depressive Disorder Neuromodulation Neurophysiology Neurotechnology Obsessive Compulsive Disorder Treatment Of Major Depressive Disorder Neuropsychology Post Traumatic Stress Disorder Treatment Of Depression Fatigue
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more BWAY news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 12.3899 |
| 52 Week Low | 8.0 |
| Average Volume | 10,066 |
| 200-Day Moving Average | 0.0 |
| 50-Day Moving Average | 10.2432 |
| 20-Day Moving Average | 10.1851 |
| 10-Day Moving Average | 10.3745 |
| Average True Range | 0.4259 |
| ADX | 20.36 |
| +DI | 16.8014 |
| -DI | 33.2472 |
| Chandelier Exit (Long, 3 ATRs ) | 9.5723 |
| Chandelier Exit (Short, 3 ATRs ) | 9.807699999999999 |
| Upper Bollinger Band | 11.0652 |
| Lower Bollinger Band | 9.305 |
| Percent B (%b) | 0.45 |
| BandWidth | 17.282108 |
| MACD Line | 0.0602 |
| MACD Signal Line | 0.0545 |
| MACD Histogram | 0.0057 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 11.36 | ||||
| Resistance 3 (R3) | 11.30 | 10.83 | 11.15 | ||
| Resistance 2 (R2) | 10.83 | 10.51 | 10.86 | 11.08 | |
| Resistance 1 (R1) | 10.46 | 10.31 | 10.23 | 10.52 | 11.01 |
| Pivot Point | 9.99 | 9.99 | 9.87 | 10.02 | 9.99 |
| Support 1 (S1) | 9.62 | 9.67 | 9.39 | 9.68 | 9.19 |
| Support 2 (S2) | 9.15 | 9.47 | 9.18 | 9.12 | |
| Support 3 (S3) | 8.78 | 9.15 | 9.05 | ||
| Support 4 (S4) | 8.84 |
